Renvela
Product Images NDC 68151-5113

4 FDA label images from Carilion Materials Management · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Renvela (NDC 68151-5113). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl681515113)

Label Image (Lbl681515113)
Label for Renvela sevelamer carbonate 800 mg tablet by Carilion Materials Management. The label includes manufacturing details, lot number B3548B01, expiration date 09/14, and a barcode with the number 0000005113. It also states 'Rx only.'*
FDA Label Image

Chemical Structure/figure 1 (Renvela 01)

Chemical Structure/figure 1 (Renvela 01)
Chemical structure diagram of the active ingredient in Renvela as indicated by the product data. The structure shows polymeric units containing ammonium, bicarbonate, amine, and hydroxyl functional groups linked in a complex arrangement.*
FDA Label Image

Figure 2 (Renvela 02)

Figure 2 (Renvela 02)
A line graph comparing the percentage of patients achieving various levels of serum phosphorus reduction between Sevelamer Hydrochloride and an active control. The x-axis represents reduction in serum phosphorus (mg/dL), ranging from worsening to improved reduction, while the y-axis shows the percentage of patients with at least that reduction, ranging from 0 to 100%.*
FDA Label Image

Figure 3 (Renvela 03)

Figure 3 (Renvela 03)
A line graph showing phosphorus change from baseline over 52 study weeks. The graph compares two treatments: Sevelamer Hydrochloride and Active-Control. The vertical axis represents phosphorus change, while the horizontal axis represents study weeks. Both treatments show an initial drop followed by a stable phase.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.